NCT02756936View on ClinicalTrials.gov

Bioequivalence Study of Daclatasvir From Daclatasvir Zeta 60 mg Film Coated Tablets (Zeta Pharm Pharmaceutical Industries, Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

February 29, 2016

Study Completion Date

March 31, 2016

Conditions

Healthy

Interventions

DRUG

Daclatasvir Zeta

1 tablet contains 60 mg Daclatasvir

DRUG

Clatazev

1 tablet contains 60 mg Daclatasvir

Trial Locations (1)

11757

Genuine Research Center GRC, Cairo

All Listed Sponsors

collaborator

Zeta Pharma Pharmaceutical Industries

INDUSTRY

lead

Genuine Research Center, Egypt

INDUSTRY

NCT02756936 - Bioequivalence Study of Daclatasvir From Daclatasvir Zeta 60 mg Film Coated Tablets (Zeta Pharm Pharmaceutical Industries, Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK) | Biotech Hunter | Biotech Hunter